Safety and Tolerability of the Dual 5 -Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic Hyperplasia

Author： Andriole G.L.   Kirby R.  

Publisher： Elsevier

ISSN： 0302-2838

Source： European Urology, Vol.44, Iss.1, 2003-07, pp. : 82-88

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

By Roehrborn C.G.   Boyle P.   Nickel J.C.   Hoefner K.   Andriole G.   the ARIA3001 ARIA3002 and ARIA3003 Study Investigators  

Urology, Vol. 60, Iss. 3, 2002-09 ,pp. : 434-441

Elsevier

Access to resources Recommend Favorite

Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia

By Dutkiewics S.  

International Urology and Nephrology, Vol. 32, Iss. 3, 2001-09 ,pp. : 423-432

Springer Publishing Company

Access to resources Recommend Favorite

Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia

By Bartsch G.   Rittmaster R.   Klocker H.  

World Journal of Urology, Vol. 19, Iss. 6, 2002-04 ,pp. : 413-425

Springer Publishing Company

Access to resources Recommend Favorite

Laser treatment of benign prostatic hyperplasia

By Kuntz Rainer  

World Journal of Urology, Vol. 25, Iss. 3, 2007-06 ,pp. : 241-247

Springer Publishing Company

Access to resources Recommend Favorite

Lasers in the treatment of benign prostatic hyperplasia

By Gerber G.S.  

Urology, Vol. 45, Iss. 2, 1995-02 ,pp. : 193-199

Elsevier

Access to resources Recommend Favorite